Jun. 11 at 5:32 PM
$TELO today announced compelling new preclinical data demonstrating that its lead drug candidate, Telomir-1, significantly reversed neurological, hepatic and kidney symptoms in a clinically relevant animal model of Wilson’s
disease.
Wilson’s disease is a rare and potentially fatal genetic disorder caused by mutations in the ATP7B gene, which impair the body’s ability to eliminate excess copper. As copper builds
up—primarily in the liver and brain—it leads to inflammation, tissue damage, and multi-organ dysfunction. Patients may experience liver failure, psychiatric disturbances, tremors, and
progressive neurological decline. $
$TELO $SPY $QQQ
